Showing 161 - 170 of 525,481
We study the effect of ageing, defined an extra year of life, on health care utilisation. We disentangle the direct effect of ageing, from other alternative explanations such as the presence of comorbidities and endogenous time to death (TTD) that are argued to absorb the effect of ageing...
Persistent link: https://www.econbiz.de/10012219358
We integrate time-inconsistent decision making due to hyperbolic discounting into a gerontologically founded life cycle model with endogenous aging and longevity. Individuals can slow down aging and postpone death by health investments and by reducing unhealthy consumption, conceptualized as...
Persistent link: https://www.econbiz.de/10012064136
that mortality rises with age and a large share of HCE is caused by proximity to death. This hypothesis has spurned a large …
Persistent link: https://www.econbiz.de/10012124855
Persistent link: https://www.econbiz.de/10012061268
There is agreement among health economists that on the whole medical innovation causes health care expenditures (HCE) to rise. This paper analyzes for which diagnoses and in which age groups HCE per patient have grown significantly faster than average HCE. We distinguish decedents (patients in...
Persistent link: https://www.econbiz.de/10012423504
There is agreement among health economists that on the whole medical innovation causes health care expenditures (HCE) to rise. This paper analyzes for which diagnoses and in which age groups HCE per patient have grown significantly faster than average HCE. We distinguish decedents (patients in...
Persistent link: https://www.econbiz.de/10012437174
Persistent link: https://www.econbiz.de/10012489038
This paper discusses the relationship between medical innovations and ageing from a health economics perspective and surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health innovations. Particular focus is on the endogeneity of...
Persistent link: https://www.econbiz.de/10012653346
remaining life expectancy and lower mortality risk relative to earlier time periods due to improvements in mortality. We examine … to determine what eligibility ages would be today and in 2050 if adjustments for mortality improvement were taken into … approximately 0.15 years annually. Failure to adjust for mortality improvement implies the percent of the population eligible to …
Persistent link: https://www.econbiz.de/10012758511
and mortality information, HCE growth was analyzed in Swiss mandatory health insurance for the years 1996 to 2011 and … understanding of shifts in chronic disease prevalence with rising age, as well as associated HCE and survival impacts of treatment …
Persistent link: https://www.econbiz.de/10011982683